nodes	percent_of_prediction	percent_of_DWPC	metapath
Alendronate—Leukaemia—Teniposide—lymphatic system cancer	0.0587	0.0587	CcSEcCtD
Alendronate—Lymphopenia—Mechlorethamine—lymphatic system cancer	0.0419	0.0419	CcSEcCtD
Alendronate—Leukaemia—Vincristine—lymphatic system cancer	0.0315	0.0315	CcSEcCtD
Alendronate—Impaired healing—Carmustine—lymphatic system cancer	0.0206	0.0206	CcSEcCtD
Alendronate—Leukaemia—Methotrexate—lymphatic system cancer	0.0153	0.0153	CcSEcCtD
Alendronate—Hypocalcaemia—Fludarabine—lymphatic system cancer	0.0152	0.0152	CcSEcCtD
Alendronate—Transaminases increased—Carmustine—lymphatic system cancer	0.0146	0.0146	CcSEcCtD
Alendronate—Oesophagitis—Fludarabine—lymphatic system cancer	0.0127	0.0127	CcSEcCtD
Alendronate—Haemoglobin—Mechlorethamine—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Alendronate—Ulcer—Bleomycin—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Alendronate—Haemorrhage—Mechlorethamine—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Alendronate—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.0102	0.0102	CcSEcCtD
Alendronate—Drug interaction—Carmustine—lymphatic system cancer	0.00959	0.00959	CcSEcCtD
Alendronate—Impaired healing—Methotrexate—lymphatic system cancer	0.00952	0.00952	CcSEcCtD
Alendronate—Alopecia—Mechlorethamine—lymphatic system cancer	0.00952	0.00952	CcSEcCtD
Alendronate—Drug interaction—Vincristine—lymphatic system cancer	0.00915	0.00915	CcSEcCtD
Alendronate—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.00908	0.00908	CcSEcCtD
Alendronate—Hypocalcaemia—Mitoxantrone—lymphatic system cancer	0.00903	0.00903	CcSEcCtD
Alendronate—Ulcer—Mitoxantrone—lymphatic system cancer	0.00874	0.00874	CcSEcCtD
Alendronate—Dysphagia—Fludarabine—lymphatic system cancer	0.00872	0.00872	CcSEcCtD
Alendronate—Stomatitis—Teniposide—lymphatic system cancer	0.00862	0.00862	CcSEcCtD
Alendronate—Musculoskeletal pain—Vincristine—lymphatic system cancer	0.00859	0.00859	CcSEcCtD
Alendronate—Vertigo—Mechlorethamine—lymphatic system cancer	0.00842	0.00842	CcSEcCtD
Alendronate—Haemoglobin—Teniposide—lymphatic system cancer	0.00798	0.00798	CcSEcCtD
Alendronate—Haemorrhage—Teniposide—lymphatic system cancer	0.00794	0.00794	CcSEcCtD
Alendronate—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00771	0.00771	CcSEcCtD
Alendronate—Infection—Mechlorethamine—lymphatic system cancer	0.0076	0.0076	CcSEcCtD
Alendronate—Stomatitis—Fludarabine—lymphatic system cancer	0.00758	0.00758	CcSEcCtD
Alendronate—Alopecia—Teniposide—lymphatic system cancer	0.00702	0.00702	CcSEcCtD
Alendronate—Haemoglobin—Fludarabine—lymphatic system cancer	0.00701	0.00701	CcSEcCtD
Alendronate—Haemorrhage—Fludarabine—lymphatic system cancer	0.00698	0.00698	CcSEcCtD
Alendronate—Erythema multiforme—Fludarabine—lymphatic system cancer	0.0066	0.0066	CcSEcCtD
Alendronate—Anaemia—Teniposide—lymphatic system cancer	0.00639	0.00639	CcSEcCtD
Alendronate—Alopecia—Fludarabine—lymphatic system cancer	0.00617	0.00617	CcSEcCtD
Alendronate—Chest pain—Teniposide—lymphatic system cancer	0.00588	0.00588	CcSEcCtD
Alendronate—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00564	0.00564	CcSEcCtD
Alendronate—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00564	0.00564	CcSEcCtD
Alendronate—Anaemia—Fludarabine—lymphatic system cancer	0.00561	0.00561	CcSEcCtD
Alendronate—Infection—Teniposide—lymphatic system cancer	0.0056	0.0056	CcSEcCtD
Alendronate—Dysphagia—Carmustine—lymphatic system cancer	0.00558	0.00558	CcSEcCtD
Alendronate—Stomatitis—Bleomycin—lymphatic system cancer	0.00555	0.00555	CcSEcCtD
Alendronate—Malaise—Fludarabine—lymphatic system cancer	0.00548	0.00548	CcSEcCtD
Alendronate—Pruritus—Mechlorethamine—lymphatic system cancer	0.00541	0.00541	CcSEcCtD
Alendronate—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00523	0.00523	CcSEcCtD
Alendronate—Myalgia—Fludarabine—lymphatic system cancer	0.00517	0.00517	CcSEcCtD
Alendronate—Haemoglobin—Bleomycin—lymphatic system cancer	0.00514	0.00514	CcSEcCtD
Alendronate—Haemorrhage—Bleomycin—lymphatic system cancer	0.00512	0.00512	CcSEcCtD
Alendronate—Discomfort—Fludarabine—lymphatic system cancer	0.00511	0.00511	CcSEcCtD
Alendronate—Infection—Fludarabine—lymphatic system cancer	0.00492	0.00492	CcSEcCtD
Alendronate—Vomiting—Mechlorethamine—lymphatic system cancer	0.00486	0.00486	CcSEcCtD
Alendronate—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00486	0.00486	CcSEcCtD
Alendronate—Stomatitis—Carmustine—lymphatic system cancer	0.00485	0.00485	CcSEcCtD
Alendronate—Rash—Mechlorethamine—lymphatic system cancer	0.00482	0.00482	CcSEcCtD
Alendronate—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00482	0.00482	CcSEcCtD
Alendronate—Feeling abnormal—Teniposide—lymphatic system cancer	0.00465	0.00465	CcSEcCtD
Alendronate—Stomatitis—Vincristine—lymphatic system cancer	0.00463	0.00463	CcSEcCtD
Alendronate—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00461	0.00461	CcSEcCtD
Alendronate—Nausea—Mechlorethamine—lymphatic system cancer	0.00454	0.00454	CcSEcCtD
Alendronate—Alopecia—Bleomycin—lymphatic system cancer	0.00452	0.00452	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00452	0.00452	CcSEcCtD
Alendronate—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00451	0.00451	CcSEcCtD
Alendronate—Haemoglobin—Carmustine—lymphatic system cancer	0.00449	0.00449	CcSEcCtD
Alendronate—Urticaria—Teniposide—lymphatic system cancer	0.00448	0.00448	CcSEcCtD
Alendronate—Haemorrhage—Carmustine—lymphatic system cancer	0.00447	0.00447	CcSEcCtD
Alendronate—Abdominal pain—Teniposide—lymphatic system cancer	0.00446	0.00446	CcSEcCtD
Alendronate—Body temperature increased—Teniposide—lymphatic system cancer	0.00446	0.00446	CcSEcCtD
Alendronate—Erythema—Bleomycin—lymphatic system cancer	0.00445	0.00445	CcSEcCtD
Alendronate—Oedema peripheral—Carmustine—lymphatic system cancer	0.0044	0.0044	CcSEcCtD
Alendronate—Dyspepsia—Fludarabine—lymphatic system cancer	0.00436	0.00436	CcSEcCtD
Alendronate—Ulcer—Methotrexate—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Alendronate—Pain—Fludarabine—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Alendronate—Constipation—Fludarabine—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Alendronate—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00417	0.00417	CcSEcCtD
Alendronate—Hypersensitivity—Teniposide—lymphatic system cancer	0.00416	0.00416	CcSEcCtD
Alendronate—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Alendronate—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00413	0.00413	CcSEcCtD
Alendronate—Anaemia—Bleomycin—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Alendronate—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Alendronate—Asthenia—Teniposide—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Alendronate—Melaena—Methotrexate—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Alendronate—Malaise—Bleomycin—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Alendronate—Pruritus—Teniposide—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Alendronate—Alopecia—Carmustine—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Alendronate—Body temperature increased—Fludarabine—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Alendronate—Erythema—Carmustine—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Alendronate—Diarrhoea—Teniposide—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Alendronate—Chest pain—Bleomycin—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Alendronate—Myalgia—Bleomycin—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Alendronate—Alopecia—Vincristine—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Alendronate—Discomfort—Bleomycin—lymphatic system cancer	0.00375	0.00375	CcSEcCtD
Alendronate—Alopecia—Mitoxantrone—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Alendronate—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Alendronate—Erythema—Mitoxantrone—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Alendronate—Infection—Bleomycin—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Alendronate—Anaemia—Carmustine—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Alendronate—Vomiting—Teniposide—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Alendronate—Asthenia—Fludarabine—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Alendronate—Rash—Teniposide—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Alendronate—Dermatitis—Teniposide—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Alendronate—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Alendronate—Headache—Teniposide—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Alendronate—Pruritus—Fludarabine—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Alendronate—Anaemia—Vincristine—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Alendronate—Photosensitivity—Methotrexate—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Alendronate—Diarrhoea—Fludarabine—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Alendronate—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Alendronate—Nausea—Teniposide—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Alendronate—Anaemia—Mitoxantrone—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Alendronate—Vertigo—Vincristine—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Alendronate—Chest pain—Carmustine—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Alendronate—Myalgia—Carmustine—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Alendronate—Malaise—Mitoxantrone—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Alendronate—Myalgia—Vincristine—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Alendronate—Infection—Carmustine—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Alendronate—Vomiting—Fludarabine—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Alendronate—Rash—Fludarabine—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Alendronate—Dermatitis—Fludarabine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Alendronate—Pain—Bleomycin—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Alendronate—Headache—Fludarabine—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Alendronate—Chest pain—Mitoxantrone—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Alendronate—Myalgia—Mitoxantrone—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Alendronate—Discomfort—Mitoxantrone—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Alendronate—Infection—Vincristine—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Alendronate—Feeling abnormal—Bleomycin—lymphatic system cancer	0.003	0.003	CcSEcCtD
Alendronate—Nausea—Fludarabine—lymphatic system cancer	0.00294	0.00294	CcSEcCtD
Alendronate—Infection—Mitoxantrone—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Alendronate—Urticaria—Bleomycin—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Alendronate—Body temperature increased—Bleomycin—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Alendronate—Pain—Carmustine—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Alendronate—Constipation—Carmustine—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Alendronate—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Alendronate—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Alendronate—Feeling abnormal—Carmustine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Alendronate—Asthenia—Bleomycin—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Alendronate—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Alendronate—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Alendronate—Pain—Vincristine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Alendronate—Constipation—Vincristine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Alendronate—Asthma—Methotrexate—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Alendronate—Pruritus—Bleomycin—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Alendronate—Pain—Mitoxantrone—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Alendronate—Constipation—Mitoxantrone—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Alendronate—Body temperature increased—Carmustine—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Alendronate—Abdominal pain—Carmustine—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Alendronate—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Alendronate—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Alendronate—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Alendronate—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Alendronate—Abdominal pain—Vincristine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Alendronate—Body temperature increased—Vincristine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Alendronate—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Alendronate—Urticaria—Mitoxantrone—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Alendronate—Hypersensitivity—Carmustine—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Alendronate—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Alendronate—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Alendronate—Vomiting—Bleomycin—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Alendronate—Rash—Bleomycin—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Alendronate—Dermatitis—Bleomycin—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Alendronate—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Alendronate—Asthenia—Carmustine—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Alendronate—Stomatitis—Methotrexate—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Alendronate—Hypersensitivity—Vincristine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Alendronate—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Alendronate—Asthenia—Vincristine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Alendronate—Diarrhoea—Carmustine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Alendronate—Nausea—Bleomycin—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Alendronate—Asthenia—Mitoxantrone—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Alendronate—Dizziness—Carmustine—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Alendronate—Haemoglobin—Methotrexate—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Alendronate—Diarrhoea—Vincristine—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Alendronate—Haemorrhage—Methotrexate—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Alendronate—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Alendronate—Vomiting—Carmustine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Alendronate—Dizziness—Vincristine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Alendronate—Rash—Carmustine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Alendronate—Dermatitis—Carmustine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Alendronate—Headache—Carmustine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Alendronate—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Alendronate—Vomiting—Vincristine—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Alendronate—Rash—Vincristine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Alendronate—Dermatitis—Vincristine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Alendronate—Headache—Vincristine—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Alendronate—Nausea—Carmustine—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Alendronate—Vomiting—Mitoxantrone—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Alendronate—Rash—Mitoxantrone—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Alendronate—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Alendronate—Headache—Mitoxantrone—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Alendronate—Alopecia—Methotrexate—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Alendronate—Erythema—Methotrexate—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Alendronate—Nausea—Vincristine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Alendronate—Dysgeusia—Methotrexate—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Alendronate—Nausea—Mitoxantrone—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Alendronate—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Alendronate—Anaemia—Methotrexate—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Alendronate—Malaise—Methotrexate—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Alendronate—Vertigo—Methotrexate—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Alendronate—Chest pain—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Alendronate—Myalgia—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Alendronate—Discomfort—Methotrexate—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Alendronate—Infection—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Alendronate—Dyspepsia—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Alendronate—Pain—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Alendronate—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Alendronate—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Alendronate—Urticaria—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Alendronate—Abdominal pain—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Alendronate—Body temperature increased—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Alendronate—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Alendronate—Asthenia—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Alendronate—Pruritus—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Alendronate—Diarrhoea—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Alendronate—Dizziness—Methotrexate—lymphatic system cancer	0.000972	0.000972	CcSEcCtD
Alendronate—Vomiting—Methotrexate—lymphatic system cancer	0.000934	0.000934	CcSEcCtD
Alendronate—Rash—Methotrexate—lymphatic system cancer	0.000927	0.000927	CcSEcCtD
Alendronate—Dermatitis—Methotrexate—lymphatic system cancer	0.000926	0.000926	CcSEcCtD
Alendronate—Headache—Methotrexate—lymphatic system cancer	0.000921	0.000921	CcSEcCtD
Alendronate—Nausea—Methotrexate—lymphatic system cancer	0.000873	0.000873	CcSEcCtD
